The association between postprandial urinary C-peptide creatinine ratio and the treatment response to liraglutide: a multi-centre observational study.

Thong KY, McDonald TJ, Hattersley AT, Blann AD, Ramtoola S, Duncan C, Carr S, Adamson K, Nayak AU, Khurana R, Hunter SJ, Ali A, Au S, Ryder RE

Diabetic medicine : a journal of the British Diabetic Association6 Dec 2013Cited by 22 (Europe PMC)

PMID24246138DOI10.1111/dme.12367PepBankPUB-24246138

Publisher page PubMedAsk about this study

Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

01HumanObservational studyOther
In adults with type 2 diabetes starting or on liraglutide, neither pretreatment nor on-treatment urinary C-peptide creatinine ratio correlated with HbA1c change in univariate analyses.
In plain wordsIn adults with type 2 diabetes on liraglutide, urinary C-peptide ratio was not linked to HbA1c change in simple analyses.
Peptide
Liraglutide
Outcome
No significant changeCorrelation of urinary C-peptide creatinine ratio with HbA1c change (univariate)
Study
n = 116
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.6 → 1.2 mg daily · 32 weeksAs given in this study (human).
Measurements
Spearman r
−0.17
pretreatment ratio
Spearman r
−0.2
on-treatment ratio
Source sentences
Summary
In univariate analyses, neither pretreatment nor on-treatment urinary C-peptide creatinine ratio correlated with HbA1c change (Spearman rank correlation coefficient, r = -0.17, P = 0.17 and r = -0.20, P = 0.19, respectively).
2 context sentences(design, population, supporting numbers)
Summary · context
One hundred and sixteen subjects (70 pretreatment, 46 on treatment) with Type 2 diabetes from 10 diabetes centres were studied.
Summary · context
A single, outpatient urine sample for urinary C-peptide creatinine ratio was collected 2 h after the largest meal of the day among two separate groups: (1) subjects initiating liraglutide (0.6 → 1.2 mg daily) or (2) subjects already treated with liraglutide for 20-32 weeks.
Report a problemFND-2424613801
02HumanObservational studyOther
In adults with type 2 diabetes on liraglutide, after adjusting for baseline HbA1c, pretreatment and on-treatment log urinary C-peptide creatinine ratio were significantly associated with HbA1c change.
In plain wordsIn adults with type 2 diabetes on liraglutide, after adjusting for baseline HbA1c, urinary C-peptide ratio was linked to how much HbA1c changed.
Peptide
Liraglutide
Outcome
Not applicableAssociation of urinary C-peptide creatinine ratio with HbA1c change (multivariate)
Study
n = 116
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.6 → 1.2 mg daily · 32 weeksAs given in this study (human).
Measurements
P value
0.048
pretreatment
P value
0.04
on-treatment
Source sentences
Summary
In multi-linear regression analyses, entering baseline HbA1c and log urinary C-peptide creatinine ratio, pretreatment and on-treatment log urinary C-peptide creatinine ratio became significantly associated with HbA1c change (P = 0.048 and P = 0.040, respectively).
2 context sentences(design, population, supporting numbers)
Summary · context
One hundred and sixteen subjects (70 pretreatment, 46 on treatment) with Type 2 diabetes from 10 diabetes centres were studied.
Summary · context
A single, outpatient urine sample for urinary C-peptide creatinine ratio was collected 2 h after the largest meal of the day among two separate groups: (1) subjects initiating liraglutide (0.6 → 1.2 mg daily) or (2) subjects already treated with liraglutide for 20-32 weeks.
Report a problemFND-2424613802
03HumanObservational studyOther
In adults with type 2 diabetes starting liraglutide, HbA1c did not change significantly in the lowest quartile of pretreatment urinary C-peptide creatinine ratio.
In plain wordsIn adults with type 2 diabetes starting liraglutide, those with the lowest urinary C-peptide ratio had no clear HbA1c change.
Peptide
Liraglutide
Outcome
No significant changeHbA1c change in lowest quartile of pretreatment urinary C-peptide creatinine ratio
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.6 → 1.2 mg daily · 32 weeksAs given in this study (human).
Measurements
HbA1c change
−3 mmol/mol
quartile 1
Source sentences
Summary
-3 ± 17 mmol/mol (-0.3 ± 1.6%) (P = 0.52)
1 context sentence(design, population, supporting numbers)
Summary · context
A single, outpatient urine sample for urinary C-peptide creatinine ratio was collected 2 h after the largest meal of the day among two separate groups: (1) subjects initiating liraglutide (0.6 → 1.2 mg daily) or (2) subjects already treated with liraglutide for 20-32 weeks.
Report a problemFND-2424613803
04HumanObservational studyOther
In adults with type 2 diabetes starting liraglutide, HbA1c fell by 11-12 mmol/mol in quartiles 2 to 4 of pretreatment urinary C-peptide creatinine ratio.
In plain wordsIn adults with type 2 diabetes starting liraglutide, HbA1c fell in those with higher urinary C-peptide ratios.
Peptide
Liraglutide
Outcome
DecreaseHbA1c change in quartiles 2 to 4 of pretreatment urinary C-peptide creatinine ratio
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.6 → 1.2 mg daily · 32 weeksAs given in this study (human).
Measurements
HbA1c change
−12 mmol/mol
quartile 2
HbA1c change
−11 mmol/mol
quartile 3
HbA1c change
−12 mmol/mol
quartile 4
Source sentences
Summary
-12 ± 15 mmol/mol (-1.1 ± 1.4%) (P = 0.003), -11 ± 13 mmol/mol (-1.0 ± 1.2%) (P = 0.002) and -12±17 mmol/mol (-1.1±1.6%) (P=0.016), respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
A single, outpatient urine sample for urinary C-peptide creatinine ratio was collected 2 h after the largest meal of the day among two separate groups: (1) subjects initiating liraglutide (0.6 → 1.2 mg daily) or (2) subjects already treated with liraglutide for 20-32 weeks.
Report a problemFND-2424613804

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.